Development of biosimilars in an era of oncologic drug shortages
Edward Li,1 Janakiraman Subramanian,2 Scott Anderson,3 Dolca Thomas,4 Jason McKinley,5 Ira A Jacobs4 1University of New England College of Pharmacy, Portland, ME, USA; 2Hanna Cancer Associates, Knoxville, TN, USA; 3Pfizer Inc, La Jolla, CA, USA; 4Pfizer Inc, New York, NY, ...
Saved in:
Main Authors: | Li E (Author), Subramanian J (Author), Anderson S (Author), Thomas D (Author), McKinley J (Author), Jacobs IA (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug tendering: drug supply and shortage implications for the uptake of biosimilars
by: Dranitsaris G, et al.
Published: (2017) -
Generics and biosimilars in oncology
by: I. A. Gopienko, et al.
Published: (2020) -
Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments
by: Tomas Gabriel Bas, et al.
Published: (2024) -
Biosimilars in Oncology: Latest Trends and Regulatory Status
by: Deeksha Joshi, et al.
Published: (2022) -
Historical Critique of the Leading Causes of Death in the United States
by: McKinley Thomas
Published: (2006)